AMENDMENT NO. 2 TO RESEARCH AND EXCLUSIVE LICENSE OPTION AGREEMENTResearch and Exclusive License Option Agreement • November 27th, 2012 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Amendment No. 2 to the Research and Exclusive License Option Agreement, dated as of November 27, 2012 (this “Amendment”), is made by and between Rexahn Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware (“Rexahn”), and Teva Pharmaceutical Industries Limited, a limited liability company organized and existing under the laws of Israel (“Teva”). Any capitalized term not defined herein shall have the meaning for such term specified in the RELO Agreement (as defined below).
